From: targetedonc.com New breast cancer diagnoses account for 31% of annual cancer diagnoses among women in the United States.1 Among those diagnoses, HER2 overexpression is observed in 25% to 30% of cases. Historically, HER2-positive (HER2+) breast cancer was considered an aggressive subtype and was associated with a poor prognosis; however, the emergence of HER2-targeted therapies such as trastuzumab has considerably …
HERO (*Her2 Radiation Optimization) Study: New Breast Cancer Study Seeks to Optimize use of Radiotherapy in Patients with Early- Stage, Low Risk, HER2-Positive Breast Cancer
New Breast Cancer Study Seeks to Optimize use of Radiotherapy in Patients with Early- Stage, Low Risk, HER2-Positive Breast Cancer NRG-BR008, also known as the “HERO” trial, is a clinical study trying to determine if treatment with HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation in patients with early-stage HER2-positive breast …
New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer
By: By Dr. Chinta Sidharthan From: news-medical.net In a recent study published in the BMJ Journal, a team of scientists from China investigated the safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib, a pan-HER inhibitor, in combination with docetaxel and trastuzumab, and compared it to that of a variety of a …
Looking Forward in the HER2-Positive Breast Cancer Space
By: Hatem Soliman, MD From: targetedonc.com Hatem Soliman, MD, medical oncologist in The Center for Women’s Oncology and assistant member of the Experimental Therapeutics Program at Moffitt Cancer Center, discusses some of the exciting research that is ongoing for patients with HER2-positive breast cancer. The HER2-positive metastatic breast cancer space has had a variety of new therapies come into play …
RNI Omission Yields Low Locoregional Recurrence in HR+, HER2– Breast Cancer
By: Russ Conroy From: cancernetwork.com Locoregional recurrence (LRR) rates appeared to be low among patients with hormone receptor (HR)–positive, ERBB2-negative breast cancer who did not receive regional node irradiation (RNI), according to findings from a secondary analysis of the SWOG S1007 trial. After a median follow-up of 6.1 years, the cumulative incidence of LRR was 0.85% in patients who underwent …
HER2+ Breast Cancer Treatment Arena May Redefine the Roles of ADCs and Targeted Agents
By: Ashling Wahner From: onclive.com The expansion of the HER2-positive breast cancer treatment landscape hinges on defined treatment sequencing in the later-line setting and further research investigating the safety and efficacy of antibody-drug conjugates (ADCs) in combination with tucatinib (Tukysa), according to Adrienne G. Waks, MD. The phase 3 HER2CLIMB-02 trial (NCT03975647) is investigating ado-trastuzumab emtansine (Kadcyla) with or without …
Dr Waks on Survival Outcomes With Chemotherapy in Small Node-Negative HER2+ Breast Cancer
By: Adrienne G. Waks, MD From: onclive.com Adrienne G. Waks, MD, physician, associate director of Clinical Research, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses breast cancer survival in patients with small node-negative HER2-positive breast cancer according to the treatment modality received. An analysis of treatment patterns and patient outcomes was conducted to clarify the benefit of systemic …
Soliman Details Testing for and Treating HER2+ Breast Cancer
By: Jordyn Sava From: targetedonc.com Over recent years, patients with HER2-positive metastatic breast cancer now have new therapies which have changed the treatment landscape in this space based on the completed and ongoing trials. The phase 3 CLEOPATRA study (NCT00567190), the efficacy and safety of pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel was compared with placebo, trastuzumab, and docetaxel in patients …
First-Line Treatments for HER2-Positive Breast Cancer
By: Hatem Soliman, MD From: targetedonc.com Hatem Soliman, MD, medical oncologist in The Center for Women’s Oncology and assistant member of the Experimental Therapeutics Program at Moffitt Cancer Center, discusses the current first-line treatment options for patients with HER2-positive breast cancer. According to Soliman, the phase 3 CLEOPATRA study (NCT00567190) evaluated the efficacy and safety of pertuzumab (Perjeta), trastuzumab (Herceptin), …
Novel Therapies Show Promise in HER2-Low HER2 Breast Cancer
By: Sonia Amin Thomas, PharmD, BCOP From: pharmacytimes.com Breast cancer is the most common cancer in the United States in women and the secondleading cause of cancer-related deaths. Treatment selection for breast cancer depends on multiple factors and can be complicated, with early- and latestage breast cancers requiring different management goals and different options to meet those goals. Upon receiving …